Hemostemix Inc. (CVE:HEM – Get Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$0.06 and traded as low as C$0.06. Hemostemix shares last traded at C$0.07, with a volume of 131,911 shares trading hands.
Hemostemix Stock Performance
The firm has a market cap of C$13.32 million, a PE ratio of -3.25 and a beta of 0.21. The company has a 50 day simple moving average of C$0.06 and a 200-day simple moving average of C$0.07. The company has a debt-to-equity ratio of -66.09, a current ratio of 0.24 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Stories
- Five stocks we like better than Hemostemix
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
